1 |
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010:CD002063.
|
2 |
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain- Barre syndrome. J Clin Immunol 2010;30:S74-78.
|
3 |
Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-BarrE syndrome. Lancet 1997;350:1747.
|
4 |
Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009;66:597-603.
|
5 |
Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.
|
6 |
Vedeler C, Wik E, Nyland H. The long-term prognosis of Guillain-Barre syndrome. Evaluation of prognostic factors including plasma exchange. Acta Neurologica Scand 1997;95: 298-302.
|
7 |
Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, Yokochi M, et al. Factors influencing outcome in Guillain-Barre Syndrome: comparison of plasma adsorption against other treatments. Clinical Neurol Neurosurg 2005;107:491-496.
|